Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD

Research output: Contribution to journalJournal articleResearchpeer-review

  1. NORDSTAR - Paving the way for a new era in asthma research

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. ERS/TSANZ Task Force Statement on the Management of Reproduction and Pregnancy in Women with Airways Diseases

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Characteristics and treatment regimens across ERS SHARP severe asthma registries

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Latent tuberculosis infection among minor asylum seekers in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. European Respiratory Society guideline on long-term management of children with bronchopulmonary dysplasia

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Treatment with methotrexate and risk of lung disease in patients with rheumatoid arthritis: a nationwide population-based cohort study from Denmark

    Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

  2. Predictors for Pulmonary Tuberculosis Treatment Outcome in Denmark 2009-2014

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Acute Lung Injury in Critically Ill Patients: Actin-Scavenger Gelsolin Signals Prolonged Respiratory Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Jan Stolk
  • Naveh Tov
  • Kenneth R Chapman
  • Pablo Fernandez
  • William MacNee
  • Nicholas S Hopkinson
  • Eeva Piitulainen
  • Niels Seersholm
  • Claus F Vogelmeier
  • Robert Bals
  • Gerry McElvaney
  • Robert A Stockley
View graph of relations

Patients with inherited α1-antitrypsin (AAT) deficiency (ZZ-AATD) and severe chronic obstructive pulmonary disease (COPD) frequently experience exacerbations. We postulated that inhalation of nebulised AAT would be an effective treatment.We randomly assigned 168 patients to receive twice-daily inhalations of 80 mg AAT solution or placebo for 50 weeks. Patients used an electronic diary to capture exacerbations. The primary endpoint was time from randomisation to the first event-based exacerbation. Secondary endpoints included change in the nature of the exacerbation as defined by the Anthonisen criteria. Safety was also assessed.Time to first moderate or severe exacerbation was a median of 112 days (interquartile range (IQR) 40-211 days) for AAT and 140 days (IQR 72-142 days) for placebo (p=0.0952). The mean yearly rate of all exacerbations was 3.12 in the AAT-treated group and 2.67 in the placebo group (p=0.31). More patients receiving AAT reported treatment-related treatment-emergent adverse events compared to placebo (57.5% versus 46.9%, respectively) and they were more likely to withdraw from the study. After the first year of the study, when modifications to the handling of the nebuliser were introduced, the rate of safety events in the AAT-treated group dropped to that of the placebo group.We conclude that in AATD patients with severe COPD and frequent exacerbations, AAT inhalation for 50 weeks showed no effect on time to first exacerbation but may have changed the pattern of the episodes.

Original languageEnglish
JournalThe European Respiratory Journal
Volume54
Issue number5
ISSN0903-1936
DOIs
Publication statusPublished - Nov 2019

ID: 59364495